Back to Startups

Antheia Bio

About Antheia Bio

Antheia Bio is focused on delivering commercial-scale shipments of thebaine, a key starting material for Narcan. The company leverages synthetic biology to produce biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines.

Business Information
Target Customers
pharmaceutical companies healthcare providers research institutions
Industry Categories
Bioscience & Disease Healthcare Systems Materials, Natural Resources & Mining
Business Model
Revenue Model B2B sales of pharmaceutical ingredients
Pricing Strategy Not publicly disclosed
Sales Channels direct sales, partnerships with pharmaceutical companies
Funding Timeline
Round Date Amount Investors
Series C Jun 04, 2025 $56.0M Unknown
Founders
C
Christina Smolke

CEO and Co-Founder

Investors

No investor information available.

Recent Mentions
johncumbers
John Cumbers @johncumbers
Jun 04, 2025

Congratulations to Christina Smolke and the @antheiabio team on closing a $56 million Series C round and delivering their first commercial-scale shipment of thebaine, a key starting material for Narcan! https://t.co/Sm5pLvAUyu https://t.co/sssOk7Egd9

johncumbers
John Cumbers @johncumbers
Jun 04, 2025

Congratulations to Christina Smolke and the @antheiabio team on closing a $56 million Series C round and delivering their first commercial-scale shipment of thebaine, a key starting material for Narcan! #synbio https://t.co/8wEuzUMBxi